KR100502389B1 - Growth promoter - Google Patents

Growth promoter Download PDF

Info

Publication number
KR100502389B1
KR100502389B1 KR10-1998-0053921A KR19980053921A KR100502389B1 KR 100502389 B1 KR100502389 B1 KR 100502389B1 KR 19980053921 A KR19980053921 A KR 19980053921A KR 100502389 B1 KR100502389 B1 KR 100502389B1
Authority
KR
South Korea
Prior art keywords
growth hormone
extracts
extract
secretion
present
Prior art date
Application number
KR10-1998-0053921A
Other languages
Korean (ko)
Other versions
KR20000038805A (en
Inventor
한 수 김
인 병 윤
순 창 권
형 국 박
여 경 윤
Original Assignee
주식회사 엘지생명과학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생명과학 filed Critical 주식회사 엘지생명과학
Priority to KR10-1998-0053921A priority Critical patent/KR100502389B1/en
Publication of KR20000038805A publication Critical patent/KR20000038805A/en
Application granted granted Critical
Publication of KR100502389B1 publication Critical patent/KR100502389B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8967—Lilium, e.g. tiger lily or Easter lily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 원지추출물, 사상자추출물, 백합추출물 및 길경 추출물로 이루어진 그룹중에서 선택된 1종 이상의 추출물을 함유하는 성장호르몬 분비촉진제 조성물에 관한 것이다. 본 발명의 조성물은 사람과 동물의 뇌하수체 배양세포 처리시 강력한 성장호르몬 분비촉진 효과를 나타내고 또한 천연약재 및 식품 원료로서도 그 안전성이 확보되므로 성장호르몬 분비 촉진을 목적으로 하는 제품에 유용하게 이용될 수 있다.The present invention relates to a growth hormone secretagogue composition containing one or more extracts selected from the group consisting of extracts from the ground, extracts from the dead, lily extracts and gilyeong extracts. The composition of the present invention exhibits a strong growth hormone secretion promoting effect in the treatment of human and animal pituitary cultured cells, and also secures its safety as a natural medicine and food raw material, and thus can be usefully used for products aimed at promoting growth hormone secretion. .

Description

성장 촉진제Growth promoter

본 발명은 성장호르몬 분비 촉진제 조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 원지추출물, 사상자추출물, 백합추출물 및 길경추출물로 이루어진 그룹중에서 선택된 1종 이상의 추출물을 함유하여 천연약재 및 식품 원료로서 안전성이 있으며 사람과 동물의 뇌하수체 배양세포 처리시 강력한 성장호르몬 분비 촉진효과를 나타내는 조성물에 관한 것이다.The present invention relates to a growth hormone secretagogue composition. More specifically, the present invention contains one or more extracts selected from the group consisting of raw extract, filamentous extract, lily extract, and cirrhosis extract, which is safe as a natural medicine and food raw material, and has strong growth in the treatment of human and animal pituitary cultured cells. It relates to a composition exhibiting a hormone secretagogue effect.

성장호르몬은 사람과 동물의 뇌하수체 전엽에서 분비되는 단백질성 호르몬으로서 사람의 경우 191개의 아미노산으로 구성되어 있으며, 분비가 이루어지기 위해서는 뇌하수체에 성장호르몬 분비를 촉진시키는 물질인 성장호르몬 분비촉진 호르몬에 의한 자극이 있어야 한다. 성장 호르몬이 생체내에서 하는 주된 기능은 간 등 말초조직에서 인슐린유사 성장인자(Insulin-like growth factor - I, IGF - I)를 생성케하여 인슐린유사 성장인자가 연골조직에 작용하여 성장을 자극하게 하고, 대사작용을 통해서 단백질 합성작용을 증가시킴으로서 근육을 증가시키고 동시에 지방조직으로부터 지방산의 산화를 증가시켜 체지방을 감소시키는 기능이 있다. 이러한 기능으로 성장호르몬은 오래전부터 왜소증(矮小症) 환자들의 치료목적으로 사용되어 왔고 근래에는 비만치료제로 연구가 확대되고 있는 실정이다.Growth hormone is a protein hormone that is secreted from the anterior pituitary gland of humans and animals. In humans, it is composed of 191 amino acids, and in order to achieve secretion, it is stimulated by growth hormone secretagogue, a substance that promotes the secretion of growth hormone into the pituitary gland. Should be there. The main function of growth hormone in vivo is to produce insulin-like growth factor (I, IGF-I) in peripheral tissues such as liver, which stimulates growth by acting on cartilage tissue. In addition, metabolism increases protein synthesis, thereby increasing muscles and at the same time increasing the oxidation of fatty acids from adipose tissue, thereby reducing body fat. With this function, growth hormone has been used for the treatment of dwarfism patients for a long time, and recently, researches are being expanded to treat obesity.

과거에 사체의 뇌하수체로부터 얻어진 성장호르몬을 투여받은 환자들에게서 크로이츠펠트-야곱병(Creutzfeldt-Jakob disease, CJD)이란 질병을 유발시킴이 밝혀지고, 1985년 후반기에 유전자 재조합 방식의 성장호르몬이 상품화되기 시작하여 대량 생산 및 공급이 가능해지고 타 질환의 감염 위험성도 없어짐에 따라 최근에는 유전자 재조합 방식의 성장호르몬만이 성장호르몬결핍 질환의 치료제로 사용되고 있다. 유전자 재조합 방식의 성장호르몬을 채내에 투여하는 방법은 성장호르몬 자체가 거대 단백질이어서 경구투여가 불가능하여 주사기를 이용한 근육주사로 이루어 지는데, 대량생산에도 불구하고 치료기간동안 요구되는 비용이 많을뿐만 아니라, 근육내 주사로 투여하므로 이에 따르는 불편함이 큰 것이 사실이었다.Creutzfeldt-Jakob disease (CJD) has been shown to cause disease in patients who received growth hormone from the pituitary gland in the past, and recombinant recombinant growth hormone was commercialized in late 1985. As the mass production and supply becomes possible, and the risk of infection of other diseases disappears, only recently, recombinant recombinant growth hormone has been used as a treatment for growth hormone deficiency disease. The method of administering the recombinant recombinant growth hormone in the mine is made by intramuscular injection using a syringe because the growth hormone itself is a huge protein, which is impossible to orally administer. It was true that discomfort caused by intramuscular injection was great.

따라서 경구투여가 가능한 성장호르몬 분비 촉진제의 개발 필요성이 제기되었고, 처음으로 1980년에 미국 툴란(Tulan) 대학교의 바우어(C.Y. Bowers) 등이 생체내의 엔케팔린(enkephalin)을 토대로 성장호르몬 분비활성을 갖는 6개의 아미노산으로 구성된 새로운 성장호르몬 분비촉진제인 GHRP - 6(Growth hormone releasing peptide - 6, His - D - Trp - Ala - Trp - D - Phe - Lys - NH2)를 개발하였다(Endocrinology, 108, 31 - 9, 1980). 이 물질은 다른 여러 과학자들에 의해 생체내에서와 외에서(in vivo & in vitro) 모두 성장호르몬을 분비시키는 활성이 있음이 확인되었고(Endocrinology, 116, 1432 - 8, 1984; Endocrinology, 117, 97 - 105, 1985), 비록 적은 흡수율이지만 경구투여시에도 흡수가 되는 것으로 보고되었다(Life Science, 47, 29-36, 1990). GHRP-6가 개발된 이후에 계속적인 연구로 다른 펩타이드성 성장호르몬 분비촉진제인 GHRP - 1(Ala - His - D - β - Nal - Ala - Trp - D - Phe - Lys - NH2)과 GHRP - 2(D - Ala - D - β - Nal - Ala - Trp - D - Phe - Lys - NH2) 이라는 6개의 변화된 펩타이드로 구성된 성장호르몬 분비촉진제가 개발, 보고되었다. 그러나 이들은 생체내의 활성은 뛰어나지만 경구투여시 그 흡수율이 2∼3%대에 머무르는 등 경구투여에는 개선의 여지가 많은 것으로 보고되었다.Therefore, the necessity of developing orally administrable growth hormone secretagogue was raised. For the first time in 1980, CY Bowers of Tulan University, U.S.A. GHRP-6 (Growth hormone releasing peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH 2 ), a growth hormone secretagogue composed of 4 amino acids, was developed (Endocrinology, 108, 31-). 9, 1980). It has been confirmed by several other scientists that it has the ability to secrete growth hormone both in vivo and in vitro (Endocrinology, 116, 1432-8, 1984; Endocrinology, 117, 97-). 105, 1985), although low absorption rates have been reported to be absorbed upon oral administration (Life Science, 47, 29-36, 1990). Subsequent studies after the development of GHRP-6 resulted in other peptide growth hormone secretagogues, GHRP-1 (Ala-His-D- β -Nal-Ala-Trp-D-Phe-Lys-NH2) and GHRP-2 A growth hormone secretagogue consisting of six altered peptides (D-Ala-D- β -Nal-Ala-Trp-D-Phe-Lys-NH 2 ) has been developed and reported. However, they have excellent activity in vivo, but the oral administration has been reported to have a lot of room for improvement, such as the absorption rate stays in 2-3%.

이러한 경구투여의 단점을 개선한 성장호르몬 분비촉진제가 게르츠등(Gertz et al., Journal of Clinical Endocrinology and Metabolism, 177, 1393 - 1397, 1993)에 의해 비펩타이드성으로 개발되었는데, 이것은 GHRP - 6의 구조를 분석하여 얻은 벤조융합 락탐(Benxo - fused lactam)구조의 L - 692, 429 라는 화합물이다. 그러나 이 화합물은 동물에서와 달리 사람에 대한 임상 실험에서 경구투여시 흡수가 그리 높지않은 문제가 있었는데, 이를 개선하여 스피로인돌린 술폰아마이드(Spiroindoline sulfonamide) 구조의 L - 163, 191 이라는 화합물이 미국 머크사에 의해 개발되었다. 이 화합물은 기존에 개발되었던 성장호르몬 분비촉진제들의 가장 큰 문제점이었던 경구 흡수율을 높인 화합물로서 개(Beagle dog)에서 경구투여시 60% 이상의 흡수율을 나타내는 것으로 보고되었고 이를 바탕으로 임상 시험이 진행중이다(Endocrinology, 137, 5284 - 5289, 1996).Growth hormone secretagogues have been developed non-peptidically by Gertz et al., Journal of Clinical Endocrinology and Metabolism, 177, 1393-1397, 1993, which ameliorate the disadvantages of oral administration. It is a compound called L-692, 429 of Benxo-fused lactam structure obtained by analyzing the structure of. However, unlike in animals, the compound had a problem that absorption was not so high in oral administration in human clinical trials that improved L-163 and 191 of the spiroindoline sulfonamide structure, Merck, USA. Developed by the company. This compound has been reported to have an oral absorption rate, which is the biggest problem of the growth hormone secretagogues developed in the past, and it has been reported to have an absorption rate of 60% or more when administered orally in Beagle dog (Endocrinology). , 137, 5284-5289, 1996).

이와 같은 화합물은 경구용 성장호르몬 분비촉진제가 갖추어야 할 체내에서의 흡수율과 성장호르몬만을 선택적으로 분비시키는 생물학적 활성도를 갖고 있어서 주사제형 성장호르몬제를 대체할 새로운 의약품으로 각광을 받을 수 있을 것이다. 이들 물질에 관한 연구결과들은 뇌하수체를 자극하여 성장호르몬만을 선택적으로 분비시키는 물질들이 주사제형 성장호르몬 대체제로서 임상적으로 유용하게 사용될 수 있음을 시사하고 있으며, 또한 새로운 성장호르몬 분비자극제의 개발이 용이하지 않다는 것을 보여주고 있다.Such a compound has the absorption rate in the body that the oral growth hormone secretagogue should have and the biological activity of selectively secreting the growth hormone alone, and thus may be spotlighted as a new drug to replace the injection growth hormone. The results of these studies suggest that substances that stimulate the pituitary gland to selectively secrete growth hormone can be used clinically as a substitute for injection growth hormone, and new growth hormone secretion stimulants are not easy to develop. It is not showing.

사람의 체내에서 성장호르몬의 분비를 조절하는 것은 44개의 아미노산으로 구성된 GHRH과 성장호르몬의 분비를 억제하는 소마토스타틴(Somatostatin)이라는 호르몬인데, 이들이 상호작용을 통해 성장호르몬을 간헐적(Pulsatile) 분비라는 특이한 형태로 분비하도록 작용하는 것으로 알려져 왔다.The secretion of growth hormone secretion in the human body is a hormone called somatostatin, which inhibits the secretion of growth hormone and GHRH consisting of 44 amino acids, the specific form of the secretion of growth hormone It has been known to act to secrete into.

그런데, GHRP - 6의 개발 이후 많은 연구자들에 의해 GHRP - 6가 GHRH 과 동일한 수용체(Receptor)를 경유하여 효과를 나타내는 것이 아니라는 보고가 있었고, 이러한 합성화합물인 성장호르몬 분비촉진제들이 경유하는 새로운 수용체의 존재 가능성이 제기되었다(Endocrinology, 114, 1573, 1984)(Endocrinology, 124, 2791, 1989). 이러한 가능성은 머크(Merk)사의 연구진에 의해 돼지와 사람의 뇌하수체 만곡형상 복층정중(Arcuate ventro - medial) 부위 그리고 시상하부에 존재하는 성장호르몬 분비촉진제 수용체의 대조핵산(cDNA, complementary DNA)의 염기서열이 밝혀지면서 사실로 입증되었다(Science, 273, 974 - 977, 1996).However, since the development of GHRP-6, many researchers have reported that GHRP-6 is not effective through the same receptor as GHRH, and that the synthetic receptor growth hormone secretagogues The possibility of existence has been raised (Endocrinology, 114, 1573, 1984) (Endocrinology, 124, 2791, 1989). This possibility has been described by Merck researchers in the nucleotide sequence of the complementary DNA (cDNA) of the growth hormone secretagogue receptor in the pig and human pituitary arch-medial and hypothalamus. This proved to be true (Science, 273, 974-977, 1996).

이러한 사실을 통해 기존에 밝혀진 성장호르몬 분비촉진호르몬과 합성화합물인 성장호르몬 분비촉진제 사이의 상승작용(synergism)이 입증되었으며, 체내에 존재하여 GHRP 와 같은 역할을 수행하리라 추측되는 물질의 규명에 더욱 관심이 증가되고 있는 실정이다.This fact proved the synergism between the previously found growth hormone secretagogue and the synthetic compound growth hormone secretagogue, and is more interested in the identification of substances that exist in the body and are expected to play a role like GHRP. This situation is increasing.

이에, 본 발명자들은 모델링 기술을 통하여 합성된 기존의 화합물과는 달리 오래 전부터 사용되어져 그 약효와 안전성이 입증된 천연 약재들중 식품으로 사용 가능한 소재들로부터 성장호르몬 분비를 유도하는 추출물을 검색하여 실험한 결과, 원지추출물, 사상자추출물, 백합추출물 또는 길경추출물이 성장호르몬 분비촉진효과가 뛰어남을 밝혀내고 이들 추출물 1종 또는 그 이상 함유시킨 성장호르몬 분비촉진제 조성물을 개발하게 되었다.Thus, the present inventors experimented by searching for extracts that induce growth hormone secretion from materials that can be used as foods among natural medicines that have been used for a long time and have proven their efficacy and safety, unlike existing compounds synthesized through modeling techniques. As a result, it was found that the extracts of the ground extract, the filamentous extract, the lily extract or the gilyeong extract have an excellent effect on the growth hormone secretion, and developed a growth hormone secretagogue composition containing one or more of these extracts.

본 발명은 원지추출물, 사상자추출물, 백합추출물 및 길경추출물로 이루어진 그룹중에서 선택된 1종 이상의 추출물을 함유하는 성장호르몬 분비촉진제 조성물을 제공한다.The present invention provides a growth hormone secretagogue composition containing one or more extracts selected from the group consisting of extracts from ground grass, filamentous extracts, lily extracts and cirrhosis extracts.

원지는 안신익지(安神益智), 거담이규(祛痰利竅), 소옹산결(消癰散結) 효능이 있고, 사상자는 온신장양(溫腎壯陽), 산한거풍(散寒祛風), 조습살충(燥濕殺蟲) 효능이 있고, 길경은 선폐거담(宣肺祛痰), 배농소옹(排膿消癰) 효능이 있고, 백합은 윤폐지혜(潤肺止咳), 청심안신(淸心安神) 효능이 있는 것으로 알려져 있었다(동의보감 및 중의학사전 참조). 그러나 선행문헌에 기재된 이런 효과들은 본 발명에서 목적으로 하는 성장호르몬 분비촉진효과와는 관계가 없다.Anji has the effect of Anxin-Izhi, Geodam Yi-gyu, and Soong-san, and the casualties are hot springs and hot winds. ), Moisturizing and insecticidal (燥濕 殺蟲) efficacy, Gil-Gyeong has a pre-lung expectoration (배), pear farming (옹) effect, lily is Yun Lung Ji-hye (潤肺 止咳), cheongsim Anshin (淸 心 安神) has been known to have efficacy (see agreement and the Chinese Medicine Dictionary). However, these effects described in the prior literature are not related to the growth hormone secretion effect aimed at the present invention.

본 발명에 따르면, 천연약재중에서 식품원료로 사용가능한 것으로 예상되는 29종의 소재, 예를들어 산사자, 삼백초, 계피, 건강, 오미자, 상백피, 소엽, 적작약, 길경, 감국, 창출, 계지, 백하수오, 원지, 사상자, 죽엽, 석창포, 오매, 복분자, 백합, 시호, 사인, 육두구, 측백엽, 몰약, 오가피, 뽕잎차, 밤잎차 및 동충하초 중에서 4종의 소재, 즉 원지, 사상자, 길경 및 백합을 물 또는 에탄올로 추출한 추출물이 성장호르몬분비 촉진효과가 탁월함을 실험적으로 밝혀내고 이들 추출물을 성장호르몬의 분비를 촉진시키는 제품에 선택사용하였다.According to the present invention, 29 kinds of materials which are expected to be used as food ingredients in natural medicines, for example mountain lions, three hundred vines, cinnamon, health, Schisandra chinensis, baekbaekpi, lobule, red peony, gilyeong, gamguk, creation, gyeji, baekhasuoh Water, four kinds of raw materials, casualties, bamboo leaves, Seokpo, five plums, bokbunja, lilies, shiho, cod, nutmeg, cypress leaves, myrrh, ogapi, mulberry leaf tea, chestnut tea and cordyceps. Or it was found experimentally that the extract extracted with ethanol is excellent growth hormone secretion effect and these extracts were selected and used in the product to promote the secretion of growth hormone.

본 발명의 조성물에서 원지추출물, 사상자추출물, 길경추출물 또는 백합추출물은 제품의 용도에 적절히 배합사용할 수 있으므로, 이들 추출물의 함량을 특별히 한정할 필요는 없는 것으로 생각되지만, 단독으로 또는 혼합물 형태로 조성물의 총중량에 대해 0.05 내지 3 중량% 사용하는 것이 좋다. In the composition of the present invention, since the extract, filamentous extract, citrus extract or lily extract can be suitably used in the use of the product, it is not necessary to specifically limit the content of these extracts, but the composition of the composition alone or in the form of a mixture It is preferable to use 0.05 to 3% by weight based on the total weight.

이하 본 발명을 실시예에 의거하여 구체적으로 설명하지만, 본 발명의 기술적 범위가 이들 실시예로 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples, but the technical scope of the present invention is not limited to these Examples.

실시예1. 물을 이용한 추출물의 제조방법Example 1 Method for preparing extract using water

오랜동안 천연약재로 사용되어 그 안전성이 확보된 천연물 중 식품원료로 사용가능한 29종의 소재(산사자, 삼백초, 계피, 건강, 오미자, 상백피, 소엽, 적작약, 길경, 감국, 창출, 계지, 백하수오, 원지, 사상자, 죽엽, 석창포, 오매, 복분자, 백합, 시호, 사인, 육두구, 측백엽, 몰약, 오가피, 뽕잎차, 밤잎차 및 동충하초)을 일반 한약도매상에서 건조상태로 구입하여 각각에 과량의 물을 첨가하여 80∼100℃로 2시간 이상 추출한 후 여과하여 얻은 여액을 농축, 동결건조하여 각각의 추출물을 얻었다.29 kinds of materials that can be used as a food ingredient among natural products that have been used as natural medicines for a long time (sansa, triticale, cinnamon, health, Schisandra chinensis, baekbaekpi, lobule, red peony, gilkyung, gamguk, creation, gyeji, baekhasuo , Raw paper, casualties, bamboo leaves, Seokpo, five plums, bokbunja, lilies, shiho, cod, nutmeg, cypress leaves, myrrh, ogapi, mulberry leaf tea, chestnut tea and Cordyceps sinensis) were purchased at the general Chinese wholesalers in excess of water. The mixture was extracted at 80-100 ° C. for 2 hours or more, and the filtrate obtained by filtration was concentrated and lyophilized to obtain respective extracts.

실시예 2. 성장호르몬 분비촉진 활성실험Example 2 Growth Hormone Secretion Activity Test

상기 실시예 1에서 얻어진 각 추출물의 성장호르몬 분비촉진 활성을 검증하기 위해서 다음과 같은 방법으로 생체외 실험(In vitro test)을 실시하였다.In order to verify the growth hormone secretagogue activity of each extract obtained in Example 1 was carried out in vitro test (In vitro test) in the following way.

약 200g의 몸무게가 나가는 스프래그 - 다우리(Sprague - Dawley) 흰쥐로부터 뇌하수체를 얻은 뒤 이를 수술용 칼로 1mm3 입방체가 될 때까지 자른 뒤, 이를 모아 히알루로니다아제(Hyaluronidase, type III)와 콜라게나아제(Collagenase, type IV)가 각각 0.2%씩 들어있는 HBSS(Hank's Balanced Salt Solution)에 넣은 뒤 37℃ 항온수조에서 15분간 방치후 꺼내어 5분간 진탕하여 단일 세포로 흩어지도록 하였다. 진탕 후 3분간 실온에서 방치하여 상등액을 모으고, 가라앉은 알갱이들은 수거하여 효소가 첨가된 새로운 HBSS에 넣어 다시 한 번 과정을 반복하였다. 여기에서 모아진 상등액과 전에 모았던 상등액을 함께 원심분리를 수행하여 효소가 첨가된 HBSS를 제거하고 가라앉은 세포만을 모은 뒤, 여기에 배양용배지(DMEM)를 넣어 섞고 이를 다시 미세한 망(cell stainer)에 통과시켜 단일세포만을 모아 37℃ CO2 항온기에서 2일간 배양하였다.The pituitary gland is obtained from Sprague-Dawley rats weighing about 200 g and then cut into a 1 mm 3 cube with a surgical knife. Genomease (Collagenase, type IV) was added to HBSS (Hank's Balanced Salt Solution) containing 0.2% each, left for 15 minutes in a 37 ℃ constant temperature water bath, and then shaken for 5 minutes to disperse into single cells. After shaking for 3 minutes at room temperature to collect the supernatant, the sunken granules were collected and put in fresh HBSS to the enzyme was repeated once again. The supernatant collected here and the supernatant collected together were centrifuged together to remove HBSS to which the enzyme was added, and only the sunk cells were collected, and then mixed with a culture medium (DMEM) and mixed in a fine cell stainer. Only single cells were collected and cultured in a 37 ° C. CO 2 incubator for 2 days.

배양후 3일째 되는 날에 세포를 1.2 x 105 개가 되도록 원심분리튜브에 모은 뒤 여기에 25mM 농도의 N-2-히드록시에틸피페라진-N'-e-에탄술폰산(N-2- hydroxyethylpiperazine-N'-e-ethanesulfonic acid, HEPES) 완충제가 첨가된 HBSS 에 녹아있던 각 추출물(6.7㎎/㎖) 1㎖씩 가하여 15분간 37℃ 항온수에서 배양하였다. 배양 후 원심분리를 통하여 세포를 제거하고 상등액만을 모아 배지 내로 분비된 성장호르몬의 양을 방사선면역 측정법으로 측정하였다.On the third day after the culture, the cells were collected in a centrifuge tube to obtain 1.2 x 10 5 cells, and then 25 mM N-2-hydroxyethylpiperazine-N'-e-ethanesulfonic acid (N-2-hydroxyethylpiperazine- 1 ml of each extract (6.7 mg / ml) dissolved in HBSS to which N'-e-ethanesulfonic acid (HEPES) buffer was added was incubated in constant temperature water at 37 ° C. for 15 minutes. After incubation, the cells were removed by centrifugation, and only the supernatant was collected. The amount of growth hormone secreted into the medium was measured by radioimmunoassay.

도 1은 상기와 같은 방법으로 쥐의 뇌하수체 세포에 처리하였때 각 추출물별 성장호르몬 분비 활성을 대조군(증류수)와 비교하여 나타낸 것이다. 제1도에 나타낸 검색결과로부터 원지추출물, 사상자추출물, 길경추출물 및 백합추출물이 다른 추출물들에 비해서 성장호르몬 분비활성이 훨씬 우수하다는 것을 확인할 수 있다.Figure 1 shows the growth hormone secretion activity of each extract compared to the control (distilled water) when treated in the rat pituitary cells in the same way as described above. From the search results shown in FIG. 1, it can be seen that the extracts of ground grass, filamentous extract, gilyeong extract and lily extract have much better growth hormone secretion activity than other extracts.

본 발명의 성장호르몬 분비 촉진제 조성물은 배양된 쥐의 뇌하수체 세포에 처리했을 때 성장호르몬 분비 유도 활성이 탁월하였다. 따라서 원지, 사상자, 길경, 백합 추출물은 향후 성장호르몬 분비 촉진을 목적으로 하는 식품이나 음료, 화장품 등에도 포괄적으로 사용될 수 있다. 또한 본 발명의 조성물은 천연약재 또는 식품 원료로서도 사용 가능하여 부작용이 없고 안전성이 확보며 또한 화합물질의 사용시에 수반되는 여러 가지 독성과 생리조절기능의 부조화 등의 문제점이 발생할 염려가 없는 이점이 있다.Growth hormone secretagogue composition of the present invention was excellent growth hormone secretion induction activity when treated in cultured rat pituitary cells. Therefore, raw paper, casualties, gilyeong, lily extract can be used comprehensively in foods, beverages, cosmetics, etc. for the purpose of promoting the growth hormone secretion in the future. In addition, the composition of the present invention can be used as a natural medicine or a food raw material has no side effects and ensures safety, and also has the advantage that there is no fear of problems such as various toxicity and physiological control functions accompanying the use of the compound.

도 1은 식품원료로 사용 가능한 29종의 약재추출물을 쥐의 뇌하수체 세포에 처리하였을 때 각 추출물별 성장호르몬 분비 활성을 대조군(증류수)와 비교하여 나타낸 것이다.Figure 1 shows the growth hormone secretion activity of each extract when treated with 29 kinds of medicinal extracts available to the rat pituitary cells compared to the control (distilled water).

Claims (3)

원지추출물, 사상자추출물, 백합추출물 및 길경추출물로 이루어진 그룹중에서 선택된 1종 이상의 추출물을 함유하는 성장 촉진제Growth promoter containing one or more extracts selected from the group consisting of raw extract, filamentous extract, lily extract and citrus extract 제 1항에 있어서, 상기 추출물이 조성물의 총량을 기준으로 0.05 내지 3 중량% 함유하는 성장 촉진제The growth promoter according to claim 1, wherein the extract contains 0.05 to 3 wt% based on the total amount of the composition. 제 1항 또는 2항에 있어서, 추출용매가 물 또는 에탄올인 성장 촉진제The growth promoter according to claim 1 or 2, wherein the extractant is water or ethanol.
KR10-1998-0053921A 1998-12-09 1998-12-09 Growth promoter KR100502389B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-1998-0053921A KR100502389B1 (en) 1998-12-09 1998-12-09 Growth promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-1998-0053921A KR100502389B1 (en) 1998-12-09 1998-12-09 Growth promoter

Publications (2)

Publication Number Publication Date
KR20000038805A KR20000038805A (en) 2000-07-05
KR100502389B1 true KR100502389B1 (en) 2005-10-19

Family

ID=19562018

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0053921A KR100502389B1 (en) 1998-12-09 1998-12-09 Growth promoter

Country Status (1)

Country Link
KR (1) KR100502389B1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100384482B1 (en) * 2000-07-26 2003-05-22 주식회사 엘지생명과학 Growth promoting composition
KR20030022655A (en) * 2001-09-10 2003-03-17 (주)내츄럴엔도텍 Pharmaceutical Compositions and Health Foods for Inducing IGF-1 Secretion
KR100463263B1 (en) * 2001-10-09 2004-12-23 경희대학교 산학협력단 Extract of Acanthopanax senticosus having longitudinal bone growth promotive effects and pharmaceutical composition containing the same
KR20030086158A (en) * 2002-05-03 2003-11-07 (주)메디엔스 Composition for accerating growth
KR20040035985A (en) * 2002-10-14 2004-04-30 (주)에이비아이 Composition for growth promotion by increasing expression of growth hormone and weight gain in quantity
KR102298839B1 (en) * 2019-01-04 2021-09-07 주식회사 디네이쳐 Method of selective extracting natural material

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920021047A (en) * 1991-05-24 1992-12-18 이해순 Manufacturing method of health food and health food
KR970064615A (en) * 1996-03-19 1997-10-13 성재갑 Herbal medicine extract to induce growth hormone secretion
KR19980067315A (en) * 1997-02-03 1998-10-15 김달래 How to prepare dietary health foods consumed by fat people
KR19990080967A (en) * 1998-04-23 1999-11-15 성재갑 Method for extracting growth hormone secretion stimulating factor from natural herbal medicine and water-soluble fast extract
KR20000000758A (en) * 1998-06-03 2000-01-15 배오성 Herb composition for promoting the secretion of growth hormone and promoter of growth hormone secretion prepared by using the composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920021047A (en) * 1991-05-24 1992-12-18 이해순 Manufacturing method of health food and health food
KR970064615A (en) * 1996-03-19 1997-10-13 성재갑 Herbal medicine extract to induce growth hormone secretion
KR19980067315A (en) * 1997-02-03 1998-10-15 김달래 How to prepare dietary health foods consumed by fat people
KR19990080967A (en) * 1998-04-23 1999-11-15 성재갑 Method for extracting growth hormone secretion stimulating factor from natural herbal medicine and water-soluble fast extract
KR20000000758A (en) * 1998-06-03 2000-01-15 배오성 Herb composition for promoting the secretion of growth hormone and promoter of growth hormone secretion prepared by using the composition

Also Published As

Publication number Publication date
KR20000038805A (en) 2000-07-05

Similar Documents

Publication Publication Date Title
KR100822352B1 (en) Method for preparing a composition by mother-of-pearl extraction, comprising integrally mother-of-pearl components, composition obtained by said method and use thereof in cosmetics and dermatology
RU2525913C1 (en) New peptide and its application
KR100502389B1 (en) Growth promoter
CA2871478C (en) Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same
CN101343317B (en) Brain peptide, preparation and uses thereof
CN101553127A (en) Livestock management for improved reproductive efficiency
KR20200140749A (en) Composition for improvement, treatment or prevention of muscular disorders, or improvement of muscular functions comprising Cudrania tricuspidata
KR930002011B1 (en) Antihypertensive and antihpotensive preparations
CN103690935B (en) Freeze-drying medicine composition containing thymalfasin
CN101054414B (en) Method of extracting and preparing deer DGF
KR100358937B1 (en) Water-soluble extract of anemarrhena asphodeloides bunge having growth hormone release stimulating activity and growth hormone release stimulating factor separated therefrom
CN111569046B (en) Application of polypeptide in preparation of medicine for treating pancreatitis and medicine containing polypeptide
RU2332866C2 (en) Dietary supplement "perstevit"
KR100521845B1 (en) Growth hormone secretagogue containing dioscin
CN102770150A (en) Composition for promoting the activity of peroxisome proliferator-activated receptor-delta
KR20220018822A (en) Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva
KR100763620B1 (en) The composition to secreat growth hormone containing Zizyphus jujuba Mill extract or betulinic acid
KR100497944B1 (en) Extract of herb for promoting release of growth hormone
KR102184804B1 (en) Composition for promoting muscle growth comprising hydrolysate of flounder or peptide isolated therefrom
SU1695869A1 (en) Method for preparation biostimulator "splenivite" of animal spleen
US20220151987A1 (en) Muscle building agent
KR100384482B1 (en) Growth promoting composition
KR100497946B1 (en) Extract of herb for promoting release of growth hormone
RU2114630C1 (en) Antidiabetic agent "samsar"
KR20030004044A (en) Extract of herb for promoting release of growth hormone

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080624

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee